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background
Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been
shown in preclinical and phase 1 studies to have antimyeloma activity.
methods
In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 patients
with relapsed myeloma that was refractory to the therapy they had received most re-
cently. Patients received 1.3 mg of bortezomib per square meter of body-surface area
twice weekly for 2 weeks, followed by 1 week without treatment, for up to eight cycles
(24 weeks). In patients with a suboptimal response, oral dexamethasone (20 mg daily,
on the day of and the day after bortezomib administration) was added to the regimen.
The response was evaluated according to the criteria of the European Group for Blood
and Marrow Transplantation and confirmed by an independent review committee.
results
Of 193 patients who could be evaluated, 92 percent had been treated with three or more
of the major classes of agents for myeloma, and in 91 percent, the myeloma was refrac-
tory to the therapy received most recently. The rate of response to bortezomib was 35
percent, and those with a response included 7 patients in whom myeloma protein be-
came undetectable and 12 in whom myeloma protein was detectable only by immuno-
fixation. The median overall survival was 16 months, with a median duration of response
of 12 months. Grade 3 adverse events included thrombocytopenia (in 28 percent of pa-
tients), fatigue (in 12 percent), peripheral neuropathy (in 12 percent), and neutropenia
(in 11 percent). Grade 4 events occurred in 14 percent of patients.
conclusions
Bortezomib, a member of a new class of anticancer drugs, is active in patients with re-
lapsed multiple myeloma that is refractory to conventional chemotherapy.
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ultiple myeloma accounts for
approximately 14,600 new cases of can-
cer and 10,800 deaths annually in the
United States.1 Although conventional chemother-
apy and high-dose therapy2 with hematopoietic
stem-cell rescue can prolong survival, few, if any, pa-
tients are cured. Salvage therapies for relapsed dis-
ease are equally disappointing,3,4 and although tha-
lidomide has shown promise,5,6 new treatments are
urgently needed.
We report here the effects of bortezomib (Vel-
cade [Millenium Pharmaceuticals], formerly known
as PS-341), a selective inhibitor of the proteasome,
in patients with multiple myeloma. The proteasome
is a multi-enzyme complex that is present in all cells.
It degrades proteins that regulate cell-cycle progres-
sion7-12
 
 and causes proteolysis of the endogenous




















which, in turn, up-regulates the transcription of pro-
teins that promote cell survival, stimulate growth,





vation also induces drug resistance in myeloma cells
and up-regulates the expression of adhesion mole-
cules involved in the resistance of myeloma cells to
drugs. In addition, it modulates the secretion by
bone marrow stromal cells of cytokines that medi-




Bortezomib, a boronic acid dipeptide and a po-
tent, selective, and reversible inhibitor of the protea-
some, is, to our knowledge, the first agent in this
class of small molecules to enter clinical trials. It is
administered intravenously in 3 to 5 seconds, rapid-
ly disappears from the vascular compartment, and
inhibits the proteasome, with a biologic half-life of
approximately 24 hours.20 Bortezomib has antitu-
mor activity in a variety of in vitro and in vivo models
of tumors, either alone21-25 or in combination with
common chemotherapeutic agents26-30 or radia-
tion.31,32 It induces apoptosis in myeloma-cell lines
and in myeloma cells from patients whose disease
is resistant to conventional therapies. Bortezomib
also down-regulates the expression of adhesion
molecules by myeloma cells and bone marrow stro-
mal cells, inhibits cell-adhesion–mediated drug re-
sistance, and decreases transcription and secretion
of cytokines in the bone marrow milieu.14,22,33,34
 







33,34 and in vitro, it enhances the antimy-
eloma activity of both conventional and novel che-
motherapeutic agents.19,33,35,36 In an in vivo study,
bortezomib inhibited tumor-cell growth and pro-
longed survival of mice carrying grafts of human
myeloma cells.21
In a phase 1 study in patients with advanced he-
matologic cancer, bortezomib showed activity in
nine patients with myeloma.37 This observation,
along with preclinical evidence of antimyeloma
activity, provided the rationale for our open-label
phase 2 study of bortezomib for the treatment of
relapsed, refractory myeloma.
patients
Study patients were at least 18 years of age, with re-
lapsed, refractory myeloma and a life expectancy of
more than three months. Measurable disease was
defined as a monoclonal immunoglobulin concen-
tration on serum electrophoresis of at least 1 g of
IgG per deciliter or 0.5 g of IgA per deciliter or uri-
nary excretion of at least 200 mg of monoclonal light
chain per 24 hours; patients with nonsecretory or
oligosecretory myeloma had other evidence of meas-
urable disease. All patients had had a relapse after
undergoing conventional chemotherapy, and their
myeloma was refractory to salvage chemotherapy,
as defined by progression during treatment or with-
in 60 days after the completion of treatment. 
Eligibility criteria included a Karnofsky perform-
ance-status score of at least 60, a serum concentra-
tion of aspartate aminotransferase or alanine ami-
notransferase no higher than three times the upper
limit of the normal range, a serum total bilirubin
concentration no higher than twice the upper limit
of the normal range, a measured or calculated creat-
inine clearance of more than 10 ml per minute, a
platelet count of at least 30,000 per cubic millimeter,
a hemoglobin concentration of at least 8 g per deci-
liter, and an absolute neutrophil count of at least 500
per cubic millimeter. Patients agreed to use contra-
ception, and women had a pregnancy test that was
confirmed to be negative before enrollment. 
All patients gave written informed consent be-
fore entering the study, which was performed in ac-
cordance with the Declaration of Helsinki; approv-
al was obtained from the institutional review board
at each of the participating centers.
study design and treatment
Patients received bortezomib (1.3 mg per square
meter of body-surface area) as an intravenous bolus
(taking three to five seconds to administer) twice
m
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weekly for 2 weeks, on days 1, 4, 8, and 11 in a 21-day
cycle. Patients with progressive disease after two
cycles or stable disease after four cycles were eligi-
ble to receive 20 mg of oral dexamethasone on the
day of and the day after each dose of bortezomib.
Participants received up to eight cycles of borte-
zomib; those in whom there was continuing clini-
cal benefit could receive additional treatment with
bortezomib in a separate extension study. Treatment
was withheld from patients with grade 3 or worse
nonhematologic toxic effects or grade 4 hemato-
logic toxic effects until the effects had diminished
to grade 1 or better; after resolution, treatment was
resumed at a dose of 1.0 mg per square meter. Fur-
ther reduction to 0.7 mg per square meter was al-
lowed, but lower doses were not permitted.
The investigators and representatives from Mil-
lennium Pharmaceuticals designed the study. The
data were collected and analyzed by medical and sta-
tistical representatives from Millennium in conjunc-
tion with the investigators. All investigators had ac-
cess to the primary data and participated in writing
this article. All participating institutions received
grant support for the conduct of the study.
assessment of efficacy
The primary end point was the overall rate of re-
sponse to bortezomib (including complete respons-
es, partial responses, and minimal responses). Sec-
ondary end points were the time to progression
during treatment with bortezomib alone or during
treatment with bortezomib in combination with
dexamethasone, survival, safety, the rate of response
to bortezomib in combination with dexamethasone,
and the quality of life. Evaluation of responses was
performed between days 15 and 18 of cycles 2, 4, 6,
and 8. Responses were assessed by an independent
review committee according to the criteria of the
European Group for Blood and Marrow Transplan-
tation (EBMT).38 
A complete response was defined by a negative
immunofixation test for myeloma protein in serum
and urine, the absence of soft-tissue plasmacyto-
mas, a normal serum calcium concentration, stable
skeletal disease, and less than 5 percent plasma cells
in the marrow in two specimens obtained six weeks
apart. Patients with insufficient data for an assess-
ment of efficacy were considered to have had a treat-
ment failure. A near-complete (immunofixation-
positive) response was defined by the absence of
myeloma protein on electrophoresis, independent
of the immunofixation-test status, stable bone dis-
ease, and a normal serum calcium concentration.
Time-to-event analysis was performed according
to the Kaplan–Meier method. The time to the first
response was defined as the time from the initial ad-
ministration of bortezomib to the first evidence of a
confirmed response. The duration of a response was
defined as the time from the achievement of a re-
sponse to progression. The time to disease progres-
sion was defined as the time from the initial admin-
istration of bortezomib to disease progression,
without censoring of data for the addition of dexa-
methasone or additional treatment with bortezomib
received during the extension study. For the analysis
of treatment with bortezomib alone, data for pa-
tients who received dexamethasone in combination
with bortezomib, additional bortezomib in the ex-
tension study, or alternative therapy, as well as for
those patients who died without a reported date of
progression, were censored at the last evaluation be-
fore they began receiving additional therapy or died.
assessment of safety and other secondary 
end points
Adverse events were assessed at each visit and grad-
ed according to the National Cancer Institute Com-
mon Toxicity Criteria (version 2.0) from the first
dose until 20 days after the last dose of bortezomib.
A neurologist performed a complete neurologic
evaluation during initial screening, during treatment
as needed, and at the end of treatment. Quality of life
was assessed with the use of the core quality-of-life
questionnaire (QLQ-C30), and the module on mul-
tiple myeloma (QLQ-MY24) of the European Organ-
ization for Research and Treatment of Cancer, the
neurotoxicity subscale of the Gynecologic Oncology
Group’s Functional Assessment of Cancer Therapy
(FACT/GOG-NTX), and the fatigue subscale of the
Functional Assessment of Chronic Illness Therapy.
These assessments were performed on day 1 of cy-
cles 1, 3, 5, and 7, as well as at the end of the study.
The time to progression during the last course of
treatment before study entry was calculated on the
basis of the date of relapse recorded by the investi-
gator. Paraprotein levels and skeletal radiographs
were reviewed to verify the progression of myeloma
during receipt of the last course of treatment.
statistical analysis
The statistical analysis specified that a lower limit of
the two-sided 90 percent confidence interval for the
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overall response rate that exceeded 10 percent would
be considered to be evidence of significant activity.
No formal comparisons of bortezomib alone with
bortezomib plus dexamethasone were planned or
conducted. We performed univariate analyses using
Fisher’s exact test for categorical factors and logistic
regression for continuous factors. In addition, we
conducted a multivariate logistic-regression analy-
sis using all prognostic factors in the model and
then using a stepwise selection method in which
terms were retained if they reached the 0.20 level of
significance. All descriptive statistical analyses were
performed with the use of SAS statistical software
(version 8.2, SAS Institute). Analysis of the time to
progression of disease during study treatment and
during the last course of treatment was performed
with the use of the fixed-effect partial-likelihood
method.39,40 An analysis of survival among pa-
tients who had a response as compared with pa-
tients who did not have a response was performed
with the use of the landmark method at the end of
cycle 2.41
patients and treatment
From February to December 2001, 14 centers en-
rolled 202 patients, 193 of whom could be evaluat-
ed. Table 1 shows selected characteristics of all 202
patients. Most (84 percent) had IgG or IgA myeloma
and advanced disease at diagnosis, 20 percent had
a Karnofsky performance-status score of 70 or less,
and 80 percent had symptoms of peripheral neurop-
athy at enrollment. The mean age was 60 years; 81
percent of the patients were white, 10 percent were
black, and 60 percent were men. Of the 193 patients
who could be evaluated, 178 had previously been
treated with three or more of the major classes of
agents for myeloma (Table 1), and the median num-
ber of previous therapies was 6 (range, 2 to 15). The
remaining 15 had received either two of the major
classes of agents or a stem-cell transplant.
The median duration of treatment with borte-
zomib was 3.8 months; 60 percent of patients com-
pleted at least four cycles of therapy, and 39 percent
received eight cycles. Of the 202 enrolled patients,
54 (27 percent) discontinued treatment early be-
cause of progressive disease, and 45 (22 percent)
discontinued treatment early because of adverse
events; more than 90 percent of these 99 patients
had not had a response to bortezomib.
efficacy
Of the 193 patients with measurable disease, 67
(35 percent) had a complete, partial, or minimal re-
sponse to bortezomib alone (Table 2). Nineteen pa-
tients had a complete or near-complete response.
The myeloma protein became undetectable by both
electrophoresis and immunofixation in 7 of these
19 patients; in the remaining 12 patients, the myelo-
ma protein became undetectable by electrophoresis,
but the immunofixation test remained positive. For
12 of the 19 patients with a complete response, the
response to bortezomib was the best response they
had had to any therapy. The patients in whom a com-
plete response was achieved were similar to the en-
tire group with respect to the extent of previous
treatment (95 percent had received at least three
major classes of drugs). Moreover, in 89 percent of
results
* Data are from standard cytogenetic analysis in 147 patients (85 percent), from 
fluorescence in situ hybridization alone in 18 patients (10 percent), and from 
analyses by other techniques in 7 patients.
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patients with a complete response, disease had been
refractory to the last therapy received. In an addi-
tional 24 percent of patients, the disease became
stable. An analysis of maximal myeloma-protein re-
sponses without the use of the EBMT criteria re-
vealed a reduction of at least 50 percent in 37 percent
of the patients, a reduction of at least 25 percent in
48 percent of the patients, and a response ranging
from a 25 percent reduction to a 25 percent increase
in 22 percent of the patients.
The median time to a first response was 1.3
months. The median time to progression of disease
among all 202 patients while they were receiving
bortezomib alone was 7 months (6.6 months with-
out censoring of the data for the addition of dexa-
methasone or additional treatment with bortezomib
in the extension study), as compared with 3 months
during the last treatment before enrollment (P=0.01
by the fixed-effect partial-likelihood method) (Fig.
1A). The median time to progression among pa-
tients with a complete or partial response to borte-
zomib alone was 13 months (12.5 months without
censoring of data for the addition of dexamethasone
or additional treatment with bortezomib in the ex-
tension study).
The median duration of the response among the
67 patients with a complete, partial, or minimal re-
sponse to bortezomib alone was 12 months (11.4
months without censoring of data for the addi-
tion of dexamethasone or additional bortezomib in
the extension study) (range, 1.3 to more than 16.7
months) (Fig. 1B); the median duration of the re-
sponse among the 19 patients with a complete or
near-complete response was 15 months (with pa-
tients who received bortezomib in the extension
study included in the analysis). Median survival
among all 202 patients was 16 months (Fig. 1C).
According to a landmark analysis, achievement of
a complete or partial response to bortezomib alone
after two cycles was associated with significantly
longer survival than that in all other patients (P=
0.007) (Fig. 1D).
Other secondary end points included additional
measures of clinical benefit. Among patients with
a complete or partial response, 89 percent had a
maximal hemoglobin increase of at least 1 g per
deciliter, and 72 percent had a maximal hemoglobin
increase of at least 2 g per deciliter. None of the pa-
tients with a complete or partial response needed
transfusions after cycle 4. Responses were also as-
sociated with increases in the platelet count, levels
of normal immunoglobulins, and Karnofsky per-
formance-status scores (see Supplementary Appen-
dixes 1 and 2, available with the full text of this arti-
cle at http://www.nejm.org). Analysis of the quality
of life among 143 patients revealed maximal im-
provements in the mean global quality-of-life score
and disease symptoms, including pain and fatigue.
Patients with a complete or partial response also
had a general improvement in global and physical-
domain scores on the QLQ-C30, as well as a de-
crease in the severity of symptoms of disease, pain,
and fatigue (see Supplementary Appendix 3, avail-
able with the full text of this article at http://www.
nejm.org).
Seventy-eight patients who had either stable or
progressive disease while receiving bortezomib
alone subsequently received dexamethasone in com-
bination with bortezomib, as specified in the pro-
tocol. A total of 74 patients could be evaluated for a
response to this combination, and 13 of these pa-
tients (18 percent) had a minimal or partial re-
sponse. In 6 of these 13 patients, the disease had
previously been refractory to corticosteroid therapy.
prognostic factors
The response to bortezomib was not influenced by
sex, type of myeloma, serum level of beta2-micro-
globulin, or type or number of previous therapies.
Older age (≥65 years) was loosely associated with
a lower response rate (32 percent, vs. 19 percent
among younger patients; P=0.06). In addition, pa-
tients with more than 50 percent plasma cells in the
bone marrow at enrollment had a lower response
rate (20 percent, vs. 35 percent among those with a
lower percentage of plasma cells in bone marrow;
P=0.03). Responses occurred in patients with ab-





Any response 67 (35)
Complete or partial response 53 (27)
Complete or near-complete response
Negative on immunofixation testing




Partial response 34 (18)
Minimal response 14 (7)
No change 46 (24)
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normalities in chromosome 13 and those without
such abnormalities (24 percent and 28 percent, re-
spectively). Only age and the percentage of plasma
cells in the bone marrow were significant predictors
of a response in the multivariate analysis (P<0.05)
(see Supplementary Appendix 4, available with the
full text of this article at http://www.nejm.org).
safety
The most common adverse events were gastroin-
testinal symptoms, fatigue, thrombocytopenia, and
sensory neuropathy (Table 3). Gastrointestinal
events were typically mild to moderate and were
manageable with routine support. The most com-
mon grade 3 adverse events were thrombocytopenia
(in 28 percent of patients), fatigue (in 12 percent),
neuropathy (in 12 percent), and neutropenia (in 11
percent). Grade 4 events (which occurred in a total
of 14 percent of the patients) included thrombocyto-
penia (in 3 percent) and neutropenia (in 3 percent),
with a single case of febrile neutropenia (<1 per-
cent). All other grade 4 adverse events occurred in
1 percent or less of the patients, and no patient had
grade 4 neuropathy. Among the 33 patients who did
not have neuropathy before beginning bortezomib
therapy, grade 3 neuropathy developed in 1 and
grade 1 or 2 neuropathy developed in 16. Overall,
12 percent of the patients required a reduction of the
dose at least once, and 4 percent of patients discon-
tinued treatment because of peripheral neuropathy.
Drug-related adverse events led to discontinua-
tion of bortezomib therapy in 36 patients (18 per-
cent); no single event accounted for discontinuation
in more than 4 percent of patients. Ten patients
(5 percent) died within 20 days after the last dose
of bortezomib, the majority of them from causes
related to progressive myeloma. In two patients
(<1 percent), the cause of death was assessed as
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Patients with a response
Patients without a response
Figure 1. Responses to Bortezomib.
Panel A shows a Kaplan–Meier plot of time to progres-
sion of disease in the 196 patients treated with bortezomib 
alone or all therapy (bortezomib plus dexamethasone) 
and the time to progression in the same 196 patients 
from the beginning of their last therapy to progression 
before entry into the study. Panel B shows the duration of 
the response in the 67 patients with a complete, partial, 
or minimal response to bortezomib alone or to borte-
zomib plus dexamethasone. Panel C shows overall surviv-
al among all 202 patients. Panel D shows overall survival 
among the patients with a complete or partial response 
and among patients without such a response; this analy-
sis was performed according to the landmark method at 
the end of cycle 2 (day 42).
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In this phase 2 trial, we evaluated the efficacy of
bortezomib in patients with relapsed, refractory my-
eloma. The overall response rate, including com-
plete responses, was 35 percent. The median dura-
tion of responses was 12 months, and there was an
increase by a factor of two to four in the time to pro-
gression with bortezomib therapy as compared with
the last therapy patients received before entering the
study. Responses were associated with increased
hemoglobin levels and decreased transfusion re-
quirements, improved quality of life, and improved
levels of normal immunoglobulins.
The rates of major responses to bortezomib in
patients with advanced, refractory myeloma are
noteworthy. Complete responses are rare in popu-
lations of patients with drug-refractory myeloma.
Although this trial was uncontrolled, we used sever-
al methods to reduce bias in assessing the response
to therapy. Each patient was used as his or her own
control in the assessment of the time to progres-
sion of disease relative to that with the last therapy
received before enrollment, and a landmark analysis
was performed to demonstrate an association be-
tween a response to bortezomib alone and survival.
In addition, the median duration of survival among
patients without a response (eight months) was
within the range (six to nine months) that was ex-
pected on the basis of the literature.3,42 It is also
noteworthy that responsiveness to bortezomib did
not correlate with most of the standard prognostic
factors, including the deletion of chromosome 13,
which predicts a poor outcome with conventional
therapy.
In our trial, 74 of the patients who could be eval-
uated (37 percent) received dexamethasone with
bortezomib after having a suboptimal response to
bortezomib alone, and an improved response was
achieved in 13 of them. Although it is impossible to
determine the contribution of each individual agent,
the findings regarding the activity of this combina-
tion of agents mirror the preclinical data22 and war-
rant further investigation.
Most adverse events could be managed with the
use of standard approaches; the incidence of grade
4 adverse events was relatively low. Severe myelosup-
pression was uncommon, and grade 4 neutropenia,
related febrile neutropenia, and sepsis were rare.
Thrombocytopenia, the most common severe ad-
verse event, developed primarily in patients with a
low base-line platelet count; it was transient, with
recovery occurring within the 10-day period during
which treatment was suspended, and was not asso-
ciated with serious bleeding complications. The pat-
tern of the thrombocytopenia is not consistent with
the pattern typically observed with conventional
chemotherapy.
The most clinically significant adverse event was
cumulative, dose-related peripheral sensory neurop-
athy. New or worsening symptoms or signs of pe-
ripheral sensory neuropathy were reported in 34
percent of patients; overall, the incidence of grade
3 peripheral neuropathy was 12 percent, and there
were no cases of grade 4 peripheral neuropathy;
moreover, complete resolution or improvement of
peripheral neuropathy was observed in the majority
of patients during the follow-up period. Grade 3
neuropathy developed during treatment in only one
discussion
 
* Adverse events reported as drug-related are those that were considered by the 
investigator to be probably or possibly related to the study drug. All 202 pa-
 
tients were included in this analysis.
 
Table 3. Drug-Related Adverse Events Reported by at Least 10 Percent 












Nausea 111 (55) 13 (6) 0 
Diarrhea 88 (44) 14 (7) 2 (1)
Fatigue 83 (41) 24 (12) 0 
Thrombocytopenia 81 (40) 56 (28) 6 (3)
Constipation 33 (16) 5 (2) 0 
Vomiting 55 (27) 16 (8) 1 (<1)
Anorexia 50 (25) 5 (2) 0 
Pyrexia 45 (22) 8 (4) 0 
Anemia 42 (21) 17 (8) 0 
Headache 38 (19) 6 (3) 0 
Peripheral neuropathy 63 (31) 25 (12) 0 
Pain in limb 27 (13) 14 (7) 0 
Neutropenia 38 (19) 22 (11) 6 (3)
Rash 31 (15) 1 (<1) 0 
Dizziness (excluding vertigo) 24 (12) 3 (1) 0 
Weakness 23 (11) 11 (5) 1 (<1)
Dehydration 20 (10) 15 (7) 0 
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patient who did not have neuropathy at base line,
suggesting that the incidence of neuropathy will be
lower in ongoing clinical trials of bortezomib in-
volving patients with earlier-stage myeloma who do
not have preexisting neuropathy.
In conclusion, the novel proteasome inhibitor
bortezomib induces clinically significant respons-
es, with manageable toxic effects, in patients with
relapsed, refractory myeloma. An international, ran-
domized, multicenter phase 3 trial comparing bor-
tezomib with high-dose dexamethasone in patients
with relapsed multiple myeloma is ongoing. The re-
sults of this trial and other ongoing studies should
provide clinical guidance as to how to use this agent
in earlier-stage disease.
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